A Multicenter Evaluation of the US Prevalence and Regional Variation in Macrolide-resistant S. pneumoniae in Ambulatory and Hospitalized Adult Patients in the US

  11 February 2021

Macrolide resistance was found in 39.5% of 3626 non duplicate Streptococcus pneumoniae isolates from adult ambulatory and inpatient settings at 329 US hospitals (2018-2019). Macrolide resistance was significantly higher for respiratory vs blood isolates and ambulatory vs inpatient admissions. Despite geographic variation, S. pneumoniae-macrolide resistance was >25% in most regions.

Author(s): Vikas Gupta, Kalvin C Yu, Jennifer Schranz, Steven P Gelone
Effective Surveillance  


Unrestricted financial support kindly provided by

Antimicrobial Resistance Fighter Coalition

Technology Database

Display your AMR Technology, Product and Service


Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.


Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!